Traditional Chinese Medicine as an Adjunctive Therapy Improves Cardiac Function and Reduces Serum Inflammatory Markers in Patients with Chronic Heart Failure
Traditional Chinese Medicine Enhances Cardiac Function in Heart Failure
Abstract
Background: To analyze the effects of traditional Chinese medicine treatment compared to standard treatment in improving cardiac function and lowering serum biomarker levels in patients with chronic heart failure (CHF).
Methods: A total of 40 CHF patients admitted to the Cardiology Department of our hospital from January 2021 to August 2023 were selected as the study subjects. They were divided into an observation group (treated with traditional Chinese medicine) and a control group (treated with Western medicine standard therapy) based on a random number table, with 20 cases in each group. The clinical efficacy, Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores before and after treatment, 6-minute walk test (6MWT) results, cardiac output (CO), ejection fraction (EF), left ventricular end-diastolic pressure (LVEDP), serum high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were observed and compared between the two groups. Adverse reaction rates were also recorded.
Results: The total effective rate of the observation group was higher than that of the control group, and the intergroup comparison showed statistical differences (P < 0.05). Before treatment, there were no statistically significant differences in MLHFQ scores, 6MWT results, CO, EF, LVEDP, serum hs-CRP, IL-6, TNF-α, and NT-proBNP levels between the two groups (P > 0.05). However, after treatment, the MLHFQ scores, LVEDP, serum hs-CRP, IL-6, TNF-α, and NT-proBNP levels in the observation group were lower than those in the control group, while the 6MWT results, CO, and EF were higher than those in the control group, and the intergroup comparisons showed statistical differences (P < 0.05). The adverse reaction rate in the observation group was lower than that in the control group, and the intergroup comparison showed statistical differences (P < 0.05).
Conclusions: Compared to standard treatment, traditional Chinese medicine treatment is more effective in improving cardiac function, enhancing exercise tolerance and quality of life, lowering serum inflammatory markers and NT-proBNP levels, and reducing the incidence of adverse reactions in patients with chronic heart failure.
References
Jia Q, Wang L, Zhang X, Ding Y, Li H, Yang Y, et al. Prevention and treatment of chronic heart failure through traditional Chinese medicine: Role of the gut microbiota. Pharmacol Res 2020; 151: 104552.
Nazarpour S, Simbar M, Khorrami M, Jafari Torkamani Z, Saghafi R, Alavi-Majd H. The association between sexual function and body image among postmenopausal women: a cross-sectional study. BMC Womens Health 2021; 21(1): 403.
Xu X, Yang Y, Zhou G, Du Z, Zhang X, Mao W, et al. Clinical Efficacy of Qili Qiangxin Capsule Combined with Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2021; 2021: 9761159.
Li X, Li D, Cui X, Zhou K, Liu J, Fan Z, et al. A Single-Central, Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial Protocol: A Clinical Effect Evaluation Study on the TCM Comprehensive Intervention Program for Chronic Heart Failure. Evidence-Based Complementary and Alternative Medicine 2021; 2021: 1-7.
Nie H, Li S, Liu M, Zhu W, Zhou X, Yan D. Yiqi Fumai Injection as an Adjuvant Therapy in Treating Chronic Heart Failure: A Meta-Analysis of 33 Randomized Controlled Trials. Evid Based Complement Alternat Med 2020; 2020: 1876080.
Chen X, Savarese G, Cai Y, Ma L, Lundborg CS, Jiang W, et al. Tai Chi and Qigong Practices for Chronic Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med 2020; 2020: 2034625.
Hong LL, Wang HS, Cheng XY, Zhang S, Zhao Y, Wang Q, et al. Evaluation and Clinical Implication of Zhenwu Decoction on Seven Cytochrome P450 Enzyme in Chronic Heart Failure Rats. Curr Drug Metab 2021; 22(9): 746-55.
Wang Y, Ma X. Relationship between changes of electrocardiogram indexes in chronic heart failure with arrhythmia and serum PIIINP and BNP. Exp Ther Med 2020; 19(1): 591-6.
Zhu Q, Li S, Ji K, Zhou H, Luo C, Sui Y. Differentially expressed TUG1 and miR-145-5p indicate different severity of chronic heart failure and predict 2-year survival prognosis. Exp Ther Med 2021; 22(6): 1362.
Wu RM, Jiang B, Li H, Dang WZ, Bao WL, Li HD, et al. A network pharmacology approach to discover action mechanisms of Yangxinshi Tablet for improving energy metabolism in chronic ischemic heart failure. J Ethnopharmacol 2020; 246: 112227.
Gao C, Zeng W, Li X, Zheng Y, Liu W. Clinical Assistant Analysis of Color Doppler Ultrasound in Diagnosis Parameters of Chronic Heart Failure. Journal of Medical Imaging and Health Informatics 2021; 11(6): 1616-22.
Zhou X, Tang G. Methodological Issues on the Study of the Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure. Am J Med 2020; 133(6): e329.
Zang Y, Wan J, Zhang Z, Huang S, Liu X, Zhang W. An updated role of astragaloside IV in heart failure. Biomed Pharmacother 2020; 126: 110012.
Shao M, Guo D, Lu W, Chen X, Ma L, Wu Y, et al. Identification of the active compounds and drug targets of Chinese medicine in heart failure based on the PPARs-RXRalpha pathway. J Ethnopharmacol 2020; 257: 112859.
Pang M, Zhi L. Research Progress of Traditional Chinese Medicine in Preventing and Treating Ventricular Remodeling by Intervening RAAS System. International Journal of Clinical and Experimental Medicine Research 2022; 6(2): 125-30.
Yu YD, Xiu YP, Li YF, Zhang J, Xue YT, Li Y. To Explore the Mechanism and Equivalent Molecular Group of Radix Astragali and Semen Lepidii in Treating Heart Failure Based on Network Pharmacology. Evid Based Complement Alternat Med 2021; 2021: 5518192.
Xu S, Wang Y, Yu M, Wang D, Liang Y, Chen Y, et al. LongShengZhi capsule inhibits doxorubicin-induced heart failure by anti-oxidative stress. Biomed Pharmacother 2020; 123: 109803.
Wang X, Gao Y, Tian Y, Liu X, Zhang G, Wang Q, et al. Integrative serum metabolomics and network analysis on mechanisms exploration of Ling-Gui-Zhu-Gan Decoction on doxorubicin-induced heart failure mice. J Ethnopharmacol 2020; 250: 112397.
Zhou Q, Meng P, Zhang Y, Chen P, Wang H, Tan G. The compatibility effects of sini decoction against doxorubicin-induced heart failure in rats revealed by mass spectrometry-based serum metabolite profiling and computational analysis. J Ethnopharmacol 2020; 252: 112618.
Yu YD, Xiu YP, Li YF, Xue YT. To Explore the Mechanism and Equivalent Molecular Group of Fuxin Mixture in Treating Heart Failure Based on Network Pharmacology. Evid Based Complement Alternat Med 2020; 2020: 8852877.
Gao K, Zhang J, Gao P, Wang Q, Liu Y, Liu J, et al. Qishen granules exerts cardioprotective effects on rats with heart failure via regulating fatty acid and glucose metabolism. Chin Med 2020; 15: 21.
Ma JY, Shi XL, Liu L, Xu GL, Zhang JW. Evaluation of nine active components of Lu-Jiao Fang in normal and hypertrophic rat myocardia via LC-MS/MS. Biomed Chromatogr 2020; 34(5): e4814.
Wen J, Ma X, Niu M, Hao J, Huang Y, Wang R, et al. Metabolomics coupled with integrated approaches reveal the therapeutic effects of higenamine combined with [6]-gingerol on doxorubicin-induced chronic heart failure in rats. Chin Med 2020; 15(1): 120.
Shi J, Luo L, Chen J, Wang J, Zhao H, Wang W. Study on the Differences between Traditional Chinese Medicine Syndromes in NYHA I-IV Classification of Chronic Heart Failure. Evid Based Complement Alternat Med 2019; 2019: 2543413.
Zeng C, Liao Q, Hu Y, Shen Y, Geng F, Chen L. The Role of Periplaneta americana (Blattodea: Blattidae) in Modern Versus Traditional Chinese Medicine. J Med Entomol 2019; 56(6): 1522-6.
Copyright (c) 2024 Chunhui Huang, Wei Zhang, Yiping Shi, Fangchao Chen, Jianru Zhou, Yonghong Zheng
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.